EVO vs PCRX
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 24, 2026
EVO
PCRX
Investment Advisor Scores
PCRX
AI Analyst Insights
Detailed Metrics Comparison
| Metric | EVO | PCRX | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 19.6078 | 6.25 | PCRX |
| PEG Ratio | 1.4223 | 11.2121 | EVO |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | -16.2% | 6.2% | PCRX |
| Earnings Growth | 0.0% | -30.0% | EVO |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 48.6/100 | 35.1/100 | EVO |
| Profit Margin | -27.5% | 2.0% | PCRX |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | STRONG BUY | EXTENDED | EVO |
Relative Price Performance (Last 90 Days)
Current Technical Phase
EVO
NeutralMixed signals - no dominant trend phase, RSI 45
PCRX
MarkupPrice above SMA50, rising 50-day trend (9.9% over 20 days), RSI 84
Fundamentals Snapshot
| Metric | EVO | PCRX |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 21.4 | 10.5 |
| Trailing P/E | — | 103.8 |
| Revenue (TTM) | — | — |
| Revenue Growth | -0.2% | 0.1% |
| Gross Margin | 0.1% | 0.8% |
| Operating Margin | -0.6% | 0.1% |
| EPS | -0.64 | 0.35 |
| Dividend Yield | — | — |